SEC Filing Summary: Zafgen, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on November 6, 2019. The report discloses the announcement of financial results for the third quarter of 2019. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in Boston, Massachusetts.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced via a press release (Exhibit 99.1), which is incorporated by reference but not detailed within the body of this 8-K text.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing text. The report indicates that the Company announced its Q3 2019 results, but the specific variances or trends are contained in the referenced press release.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within the text provided. It explicitly states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting the legal liability of the statements contained in the referenced press release.
Investor Verification Checklist
- Verify the specific Q3 2019 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the company name is Zafgen, Inc. (Ticker: ZFGN), as the input metadata incorrectly referenced Larimar Therapeutics, Inc.
- Review the full press release for any updated operational milestones or clinical trial data not summarized in this 8-K.
- Check subsequent filings for any restatements or updates to the Q3 2019 results.